News

Promedior‘s investigational therapy for idiopathic pulmonary fibrosis (IPF) — PRM-151 — continues to benefit patients after 76 weeks of treatment, slowing the decline in lung function and exercise capacity, while maintaining a similar safety profile as previous studies of PRM-151, an extension study shows. The results were…

Naftopidil treatment causes growth arrest of human lung fibroblasts and reduces fibrotic lesions in mice with idiopathic pulmonary fibrosis (IPF), a study shows. The findings of the study, “Naftopidil reduced the proliferation of lung fibroblasts and bleomycin‐induced lung fibrosis in mice,” were published in the Journal…

Bridge Biotherapeutics’ investigational therapeutic candidate BBT-877 for idiopathic pulmonary fibrosis (IPF) was found to be safe and well-tolerated in the single-ascending dose phase of a Phase 1 trial with healthy volunteers, the company announced. BBT-877 is currently undergoing testing in the multi-ascending dose phase, and Bridge Biotherapeutics is planning a…

Measuring three specific biomarkers — nitric oxide, PGE2, and 8‐isoprostane — in the exhaled breath condensates (EBC) or bronchoalveolar lavage fluids (BALF) of patients with different forms of interstitial lung disease or other lung diseases does not show diagnostic potential, a study suggests. The study, “Exhalative Breath Markers Do…

With 250 rare diseases newly identified every year, scientists can barely keep up — even as the healthcare system fails millions of Americans whose rare diseases have already been diagnosed. That’s the warning from Christopher P. Austin, MD, director of the National Center for Advancing Translational Studies(NCATS) at the…

Loss of productivity in the workplace is common among patients with fibrotic interstitial lung disease (ILD), and is associated with symptom severity and higher costs, according to data from a Canadian registry study. The study, “Costs of Workplace Productivity Loss in Patients with Fibrotic Interstitial Lung Disease,” was…

High levels of nitric oxide in the lungs of people with idiopathic pulmonary fibrosis (IPF) are associated with faster disease progression and worse survival, researchers in Italy report. The findings were described in the study “Alveolar concentration of nitric oxide as a prognostic biomarker in idiopathic…

Lung injuries caused during the progression of pulmonary fibrosis can lead to an increase in two inflammatory proteins, IL-6 and IL-33, which can trigger muscle damage and weight loss, a mouse study says. The study, “Elevation of IL-6 and IL-33 Levels in Serum Associated with Lung…

Rosavin, an active compound found in the plant Rhodiola rosea, commonly known as golden root or Aaron’s rod, can prevent pulmonary fibrosis (PF) manifestations in mice, a study has found. This discovery, published in the journal Biomedicine & Pharmocotherapy, suggests that rosavin may be a promising candidate…

Contrary to what has been suggested, antacid therapies may not change survival or disease progression rates among people with idiopathic pulmonary fibrosis (IPF), an Australian study found. The study, “Gastroesophageal reflux and antacid therapy in IPF: analysis from the Australia IPF Registry,” was published in the journal…